PuSH - Publication Server of Helmholtz Zentrum München

Kerth, H.A. ; Kächele, M. ; Müller, N. ; Singh, S. ; Tulessin, M.* ; Sacherl, J. ; Ates Öz, E. ; Su, J. ; Bester, R. ; Miko, S. ; Steiger, K.* ; Mogler, C.* ; Busch, D.H.* ; Wettengel, J.M. ; Protzer, U. ; Kosinska, A.

Therapeutic hepatitis B vaccine employing DNA prime – MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response.

Front. Immunol. 17:1771887 (2026)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Therapeutic vaccines offer hope for a curative treatment of chronic hepatitis B virus (HBV) infection. We developed a therapeutic hepatitis B vaccine, TherVacB, which employs priming with adjuvanted HBV S (HBsAg) and Core antigens of a single genotype, and a boost with a pan-genotypic Modified Vaccinia Ankara vector (MVA-HBVac) expressing several viral proteins that cover more than 95% of HBV circulating strains. Priming immunization with antigens exactly matching those expressed by the MVA may improve the efficacy of TherVacB. However, recombinant protein antigens need to be produced separately and require complex and costly purification, as well as a Th1-inducing adjuvant, to elicit CD8+ T-cell responses. These limitations may be overcome by DNA vaccines, which enable the direct expression of several antigens in vivo. Here, we investigated the potential of DNA vaccination as an alternative to protein priming to broaden and enhance HBV-specific immunity. Immunization of HBV-carrier mice with a DNA prime-MVA boost regimen elicited robust HBV-specific CD8+ T-cell responses, capable of reducing serum HBeAg levels and eliminating HBV-infected hepatocytes. However, it yielded poor neutralizing anti-HBs titers, resulting in an inefficient reduction of circulating HBsAg. Including adjuvanted HBsAg into DNA priming, either simultaneously or sequentially, significantly enhanced HBsAg-to-anti-HBs seroconversion rates. Still, only the sequential application supported vigorous plasmid-mediated CD8+ T-cell immunity. Interestingly, sequential immunization with DNA, followed by HBsAg and MVA, elicited neutralizing anti-HBs antibodies and enhanced HBV-specific CD8+ T-cell responses, resulting in a more potent antiviral effect compared to the reverse priming regimen. Our study demonstrates that although DNA can successfully prime an effective antiviral CD8+ T-cell response, it requires additional immunization with adjuvanted HBsAg to elicit satisfactory neutralizing antibody titers. In addition, it demonstrates that the sequence of immunizations in multicomponent heterologous-prime boost regimens is crucial and can significantly affect the quantity and quality of induced immune responses.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Hbsag ; Priming (agriculture) ; Antigen ; Dna Vaccination ; Hepatitis B Virus ; Immunization ; Vaccination ; Hbeag ; Antibody; Virus Type-1 Gag; T-cell; Immunization; Immunogenicity; Vectors; Antigen; Cd8(+); Mice; Replication; Increases
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Journal Frontiers in Immunology
Quellenangaben Volume: 17, Issue: , Pages: , Article Number: 1771887 Supplement: ,
Publisher Frontiers
Publishing Place Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Reviewing status Peer reviewed
Institute(s) Institute of Virology (VIRO)
Grants Turkish Ministry of Education (YLYS)
DZIF maternity leave program
Stiftung der Deutschen Wirtschaft" (SDW, German industrial foundation)
MD scholarships from DZIF
TherVacB PLUS project - German Federal Ministry for Technology and Research (BMFTR)
EU
German Research Foundation (DFG)